Sentences with phrase «inhibiting human platelet»

DG041 is a novel, first - in - class, orally - administered small molecule which has been shown in preclinical studies to be a selective and potent antagonist of the EP3 receptor for prostaglandin E2 (PGE2), inhibiting human platelet aggregation in a dose - dependent manner.

In preclinical in vitro studies DG041 has been shown to inhibit human platelet aggregation induced by PGE2, and to do so in a dose - dependent manner.